A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury

Sandrine Delbary-Gossart,1,* Sangmi Lee,2,* Marco Baroni,3 Isabelle Lamarche,4 Michele Arnone,4 Benoit Canolle,4 Amity Lin,2 Jeffrey Sacramento,2 Ernesto A. Salegio,2 Marie-Noëlle Castel,4 Nathalie Delesque-Touchard,4 Antoine Alam,4 Patricia Laboudie,4 Badia Ferzaz,4 Pierre Savi,4 Jean-Marc Herbert,4 Geoffrey T. Manley,2 Adam R. Ferguson,2 Jacqueline C. Bresnahan,2 Françoise Bono1 and Michael S. Beattie2

*These authors contributed equally to this work.

The p75 neurotrophin receptor is important in multiple physiological actions including neuronal survival and neurite outgrowth during development, and after central nervous system injury. We have discovered a novel piperazine-derived compound, EVT901, which interferes with p75 neurotrophin receptor oligomerization through direct interaction with the first cysteine-rich domain of the extracellular region. Using ligand binding assays with cysteine-rich domains-fused p75 neurotrophin receptor, we confirmed that EVT901 interferes with oligomerization of full-length p75 neurotrophin receptor in a dose-dependent manner. Here we report that EVT901 reduces binding of pro-nerve growth factor to p75 neurotrophin receptor, blocks pro-nerve growth factor induced apoptosis in cells expressing p75 neurotrophin receptor, and enhances neurite outgrowth in vitro. Furthermore, we demonstrate that EVT901 abrogates p75 neurotrophin receptor signalling by other ligands, such as prion peptide and amyloid-β. To test the efficacy of EVT901 in vivo, we evaluated the outcome in two models of traumatic brain injury. We generated controlled cortical impacts in adult rats. Using unbiased stereological analysis, we found that EVT901 delivered intravenously daily for 1 week after injury, reduced lesion size, protected cortical neurons and oligodendrocytes, and had a positive effect on neurological function. After lateral fluid percussion injury in adult rats, oral treatment with EVT901 reduced neuronal death in the hippocampus and thalamus, reduced long-term cognitive deficits, and reduced the occurrence of post-traumatic seizure activity. Together, these studies provide a new reagent for altering p75 neurotrophin receptor actions after injury and suggest that EVT901 may be useful in treatment of central nervous system trauma and other neurological disorders where p75 neurotrophin receptor signalling is affected.

1 Evotec, 195 route d’Espagne, 31036 Toulouse cedex, France
2 Brain and Spinal Injury Center, Department of Neurological Surgery, University of California, San Francisco, 1001 Potrero Ave, San Francisco, CA 94110, USA
3 Sanofi Research, Exploratory Unit, Via Gaetano Sbodio 2, 20134 Milano, Italy
4 From Sanofi Research, Early to Candidate, 195 route d’Espagne, 31036 Toulouse cedex, France

Correspondence to: Michael S. Beattie, PhD,
Brain and Spinal Injury Center, Department of Neurological Surgery,
Box 0899, University of California at San Francisco,
1001 Potrero Ave, Bldg 1, Rm 101, San Francisco, CA 94143, USA
E-mail: Michael.Beattie@ucsf.edu
Introduction

The p75 neurotrophin receptor (p75NTR, encoded by NGFR) is a transmembrane glycoprotein member of the TNF receptor (TNFR) superfamily, characterized by four cysteine-rich domains (CRDs) in its extracellular region (Underwood and Coulson, 2008). P75NTR binds to many neurotrophins with similar affinity (10⁻³ M) to mediate various functions (Hempstead, 2002). p75NTR as a monomer can interact with tropomyosin receptor kinase (Trk; TrkA, B and C, encoded by NTRK1, NTRK2 and NTRK3, respectively) and potentiate Trk signalling, leading to neuronal survival, neurite outgrowth, and axonal regeneration (Chan et al., 2000). However, p75NTR can also mediate cell death through pro-apoptotic signalling in neurons, oligodendrocytes and Schwann cells, linked to the binding of pro-neurotrophins (pro-NGF, pro-BDNF) (Chan et al., 2000; Beattie et al., 2002; Roux and Barker, 2002; Gentry et al., 2004; Underwood and Coulson, 2008). Recent work has also shown that aggregated oligomers (prion peptide fragment PrP, amyloid peptide) interact with p75NTR leading to cell death in vitro (Dechant and Barde, 2002; Hempstead, 2002; Roux and Barker, 2002; Gentry et al., 2004), and that p75NTR oligomers cooperate with many different protein partners (Nogo receptor, LINGO1, sortilin) to form multimeric receptor complexes leading to apoptosis and axonal outgrowth inhibition (Nykjaer et al., 2005; Hempstead, 2006).

Many TNF superfamily members exist as pre-assembled oligomers on the cell surface before ligand binding, through a specific self-association domain, the pre-ligand assembly domain (PLAD; Chan et al., 2000). This amino acid sequence, located in the CRD1 of the receptor, mediates receptor assembly, allowing ligand binding and receptor functioning (Chan, 2007). Such a domain has not yet been identified for p75NTR.

Although p75NTR is mainly expressed as a 75 kDa transmembrane glycoprotein, there is a protein isoform of p75NTR (s-p75NTR) that arises from alternative splicing of exon III and lacks the CRDs 2–4 (Roux and Barker, 2002). Soluble p75NTR (s-p75NTR) is critical for development of both the nervous and vascular systems (von Schack et al., 2001). Although s-p75NTR is unable to bind neurotrophins, cross-linked s-p75NTR might be activated through the pre-ligand assembly domain (Della-Bianca et al., 2001; Yaar et al., 2002).

P75NTR expression is limited in adulthood to some peripheral tissues and a few brain regions (Schor, 2005). However, injury-induced p75NTR expression has been reported in vivo in various CNS pathologies (Beattie et al., 2002; Dechant and Barde, 2002; Turner et al., 2004; Diarra et al., 2009). Reduction of p75NTR activity can protect cortical neurons from cell death after close axotomy (Harrington et al., 2004), and a novel peptide antagonist of the p75NTR protects oligodendrocytes after spinal cord injury and promotes better neurological recovery (Tep et al., 2013). Thus, p75NTR interactions with co-receptors could provide a target for both neuroprotection and enhancement of axonal growth, if it were possible to reduce p75NTR homodimerization or interactions with ‘negative’ co-receptors while simultaneously enhancing heterodimerization with TrkA. To that end, we attempted to find selective inhibitors of p75NTR pre-ligand dimerization able to block both s-p75NTR and p75NTR signalling, and to modulate Trks/p75NTR signalling. Recently, we identified EVT901 as such an antagonist of p75NTR, and here, report that EVT901 inhibits p75NTR oligomerization in vitro while increasing TrkA phosphorylation, blocks apoptosis and increases neurite outgrowth in neuroblastoma cells. In cortical oligodendrocyte cultures, EVT901 reduced p75NTR expression and cell death produced by proNGF. In vivo, traumatic brain injury (TBI) increased the expression of both p75NTR and proNGF in both controlled cortical impact (CCI-TBI) and fluid percussion injury (FPI-TBI) models of TBI, and EVT901 showed neuroprotection in both models, and reduced post-TBI seizure susceptibility. Together, these results suggest the utility of targeting p75NTR oligomerization in CNS trauma, and provide a novel drug that may be useful in CNS injuries and neurodegenerative disorders.

Materials and methods

Animals

Adult male Long-Evans rats (~225 g, Simonsen Laboratories) were used for CCI-TBI study. All animal experiments were approved by the Institutional Laboratory Animal Care and Use Committee of University of California San Francisco and performed in compliance with NIH guidelines. Adult male Sprague Dawley rats (170–230 g, strain RjHan) were used for the FPI-TBI study. All animal treatment procedures described in this aspect of the study were approved by the Animal Care and Use Committee of Sanofi. The animal facilities are fully accredited by Association for Assessment and Accreditation of Laboratory Animal Care International.
(AAALAC). Rats were housed individually and maintained on a 12 h light/dark cycle with free access to food and water.

**In vitro assays to examine EVT901 effects on p75NTR oligomerization**

**Human cell lines**

Human Embryonic Kidney (HEK) 293T cells and human neuroblastoma SHSY-5Y cells were from ATCC [authenticated by the provider using short tandem repeat (STR) profiling]. Neuroblastoma SK-N-BE p75NTR (BEp75) cell line, stably expressing the human full-length p75NTR, was kindly provided by Della Valle G (Department of Genetics and Microbiology, University of Pavia, Italy), and the molecular analyses have been previously described (Bunone et al., 1997). All cell lines were maintained in appropriate media supplemented with foetal calf serum and glutamine and were tested for mycoplasma contamination.

**Construction of p75NTR-tagged proteins**

The human full-length p75NTR was reverse-transcribed and amplified from SKNBE-p75NTR cells. The PCR product was subcloned into the pDisplay vector to obtain the construct HA-p75NTR or into pCMV-Tag4A to obtain Flag-p75NTR. The CRD1p75NTR construct, inserted into the pDisplay vector, contains sequences representing the first CRD (AA29-64) directly linked to amino acid residues 214–427 of the receptor p75NTR (deletion of CRD2–4). Chimera CRD1-CD40 is composed of the first CRD of p75NTR (AA29-64, fragment 1) linked to human CD40 receptor deleted in CRD1 (AA60–277, fragment 2) inserted into the pDisplay vector. The human CD40 full-length (AA1-277) was cloned into the pCI-neo vector (Fig. 1E).

Concerning the AP-p75NTR construct, alkaline phosphatase (AP) was fused to the NH2-terminus of the extracellular domain of the receptor p75NTR (containing the CRDs 1–4) and cloned into pcDNA-FRTV5His TOPO® vector to obtain a soluble form of p75NTR tagged with alkaline phosphatase. All the resulting cDNAs for the different constructs were sequenced to verify the correct reading frame.

**Binding of soluble AP-p75NTR**

Binding experiments were performed on SKNBE-p75NTR using a soluble form of the receptor p75NTR fused to alkaline phosphatase (AP-p75NTR) as ligand obtained after transient transfection of HEK293T cells for 3 days. Briefly, SKNBE-p75NTR cells (2.5 × 10⁶ cells/well) were plated in 96-well plates for 24 h, and preincubated (37°C) for 1 h with increasing concentrations of EVT901 followed by addition of 10 nM AP-p75NTR for 1 h. Cells were filtered (Skatron), separately collected with addition of specific substrate (CDP star) for measurement of alkaline phosphatase activity.

**Binding of NGF**

Binding of 125I-NGF (2000 Ci/mM, Amersham) was carried out on cell suspensions of SK-N-BE cells according to the method described by Weskamp and Reichardt (1991). The specific binding was defined as the difference between the total binding and the non-specific binding [measured after 1 h of preincubation of the cells with unlabelled NGF (1 µM)]. Competition experiments were done with 0.3 nM of 125I-NGF and preincubating with increasing doses of EVT901.

**Oligomerization of tagged p75NTR**

HEK293T cells (3 × 10⁶ cells/flask) were transiently cotransfected for 24 h with equal amount of DNA from the p75NTR full-length tagged either in NH2-terminal with an haemagglutinin A epitope tag (HA) (HA-p75NTR) or in C-terminal with a Flag epitope tag (Flag-p75NTR), using the FuGENE® 6 reagent (Roche Applied System). After treatment for 24 h with EVT901, cells were lysed and the supernatants were collected. Equal amounts of proteins were dispatched onto anti-flag M2 coated 96 well plates (Sigma-Aldrich) for 1 h at room temperature, followed by washing, incubation with anti-HA horseradish peroxidase (HRP), and reaction with specific substrate. Quantification was measured using a microplate fluorometer and expressed as OD (450 nm reading). Error bar indicates ± standard error of the mean (SEM).

**Induction of cell death**

SH-SY5Y cells (1.5 × 10⁶ cells/ml in 35-mm collagen-coated dishes) were stimulated for 48 h with pro-NGF (10 ng/ml, SCIL proteins), PrP106-126 (25 µM, Bachem), or amyloid-β1–40 (10 µM, Bachem) in presence or not of EVT901. Apoptosis was evaluated with a photometric enzyme immunoassay (cell death detection ELISA, Roche) for the quantitative detection of cytoplasmic mono- and oligonucleosomes. Results are expressed as per cent of inhibition of apoptosis versus untreated. For studies with HEK293T, cells were transiently transfected with the same amount of DNA from different constructs: empty vector (control), full-length of p75NTR (p75NTR), short-form of p75NTR (CRD1-p75NTR), full-length of CD40, or a chimera CD40-CRDp75NTR, and for specificity studies with FAS, TNFR1, TNFRII, HVE-M, LTβR, 4.1BB, or BCMA receptors. Then, cells were treated with EVT901 (100 nM) for 24 h, and apoptosis was measured and expressed as mean number of oligonucleosomes/10⁶ cells. Error bar indicates ± SEM.

**Neuritogenesis of SH-SY5Y cells**

SH-SY5Y cells (7.5 × 10⁴ cells/well) were incubated in collagen-coated 8-well plates overnight at 37°C, then treated in serum-free medium, with either recombinant human NGF (10 ng/ml, R&D systems) or different concentrations of EVT901, and maintained in the same media for 3 days at 37°C. The neurite length was visualized after staining with May–Grunwald–Giemsa and digitally photographed from randomly selected image fields.

**Quantification of TrkA phosphorylation**

Confluent SH-SY5Y cells were serum-deprived, and treated with NGF (10 ng/ml) or EVT901 (100 nM) for 1 to 3 days. After cell lysis, equal amounts of total protein were used for quantification of the levels of total TrkA or phosphorylated TrkA (Tyr490) using specific sandwich ELISA kits (PathScan, Cell Signaling). Results are expressed as OD₄₅₀. Error bar indicates ± SEM.
Figure 1  Mechanism of action through the CRD1 domain of p75NTR: cellular response and induction of neuritogenesis. (A) EVT901 inhibits the binding of AP-p75NTR to the receptor p75NTR. Binding experiments on SKN-BE-p75NTR with soluble AP-p75NTR (10 nM) in the presence of increasing concentrations of EVT901. Data are reported as mean % inhibition of binding, representative of three independent experiments. (B) Competition of [125I]-NGF binding with EVT901. Binding of [125I]-NGF (0.3 nM) to SKNBE-p75NTR in the presence of increasing concentrations of EVT901. Results are mean % inhibition of specific binding, representative of three independent experiments. (C) HEK293T cells transiently co-transfected with the same amount of DNA originating from the p75NTR full-length tagged either in C-terminal with HA (HA-p75NTR) or in N-terminal with Flag (Flag-p75NTR) and then treated or not with the compound EVT901 at 100 nM for 24 h. Oligomerization evaluated using an ELISA assay with flag-coated plates and anti-HA-HRP antibody [two-way ANOVA, EVT901 dose effect, F(4,94) = 46.85, P < 0.0001; Tag, F(3,94) = 594.40, P < 0.0001; EVT901 dose × Tag, F(12,94) = 46.82, P < 0.0001]. ***P < 0.0001 compared to 0. Data are indicated as mean ± SEM from six independent experiments. (D and E) HEK293T cells transiently transfected for 2 days with the same amount of DNA originating from the indicated constructs: empty vector (control), full-length of p75NTR (p75NTR), short-form of p75NTR (CRD1-p75NTR), full-length of CD40 (CD40),...
Primary oligodendrocyte cell culture

Primary oligodendrocyte cell culture was performed as described previously (Miller et al., 2007; Veiga et al., 2011). Briefly, postnatal Day 1–2 Sprague Dawley rat pups were sacrificed by decapitation and the cerebral cortices were removed and placed in the dissecting media with antibiotic/antimotic (Sigma) containing 7.1 mg/ml NaCl, 0.36 mg/ml KCl, 0.166 mg/ml KH2PO4, 2.57 mg/ml D-Glucose, 2.4 mg/ml NaHCO3, 0.01 mg/ml phenol red, 0.9 mg/ml bovine serum albumin (BSA) Fraction V, and 0.33 mg/ml MgSO4. The cortices were minced by pipetting with a 10 ml pipette plus trypsin (10 × trypsin solution, Sigma) and incubated for 20 min at 37°C. Next, DNase (10 × DNase, Sigma) and trypsin inhibitor (10 × trypsin inhibitor, Sigma) were added and pipetted with a 10 ml pipette until the suspension was homogenous. The suspension was filtered through 180 μm nylon net filters (Millipore) and then centrifuged at 2000 rpm for 5 min. Cells were resuspended in media [Dulbecco’s modified Eagle medium (Gibco) including 10% foetal bovine serum, 292 μg/ml L-glutamine (Sigma), 1 mM sodium pyruvate (Invitrogen) and 0.04 mg/ml gentamicin (Invitrogen)], filtered through 180 μm nylon mesh, Fisher), and then centrifuged at 300 relative centrifugal force (rcf) for 5 min. Cells were resuspended in media. Cells were counted using a haemocytometer and placed in T-75 flasks (1.5 × 107 cells/flask). Flasks were incubated in the same media for 3 days. The neurite length was visualized after staining with May-Grünwald-Giemsa and digitally photographed from randomly selected image fields (magnification × 10). (I) Confluent SH-SY5Y cells serum-deprived, and treated with NGF (10 ng/ml) or EVT901 (100 nM) for different times (1–3 days). Quantification of levels of total TrkA or phosphorylated TrkA (Tyr490) expressed as OD490 and representative of three independent experiments.

Treatment with proNGF and EVT901

Studies were done to determine the optimal concentration of proNGF to induce apoptotic cell death in OPC and oligodendrocyte cultures: 0.5–100 ng/ml of proNGF (cleavage resistant mutant mouse proNGF, Alamone) was added to the OPC or oligodendrocyte media and incubated for 24 h. For inhibition studies, 0, 1, 10, 30, 100, and 300 nM of EVT901 were added into the media. Mouse proNGF (50 ng/ml) was added to induce apoptotic cell death in OPC/oligodendrocyte cells and cells were kept for 24 h at 37°C in a 5% CO2 incubator. Sample size was determined based on previous studies (Miller et al., 2007; Veiga et al., 2011).

Figure 1

Continued

or a chimera of CD40 and the CRD1 domain of p75NTR (CD40-CRD1-p75NTR) (E), and then treated or not with the compound EVT901 at 100 nM for 24 h. Apoptosis quantified using an ELISA kit and data are expressed as mean number of oligonucleosomes/106 cells ± SEM, three independent experiments. Two-way ANOVA [EVT901 dose effect, F(1,168) = 33.81, P < 0.0001; constructs, F(6,134) = 28.34, P < 0.0001; EVT901 dose effect × constructs, F(6,134) = 6.75, P < 0.0001]. ***p < 0.001 (EVT901 versus untreated), ###p < 0.001 (untreated control versus untreated constructs). (F) HEK293T cells transiently transfected for 24 h with the indicated constructs: empty vector (control), full-length of p75NTR (p75NTR), FAS, TNFR1, TNFRII, HVEM, LTβR, 4.1BB, or BCMA receptors, and then treated or not with the compound EVT901 at 100 nM for 24 h. Apoptosis was quantified by measuring the mean number of oligonucleosomes/106 cells ± SEM. Data are representative of two independent experiments. Two-way ANOVA [EVT901 dose effect, F(3,134) = 8.75, P < 0.0001; constructs, F(8,134) = 28.34, P < 0.0001; EVT901 dose effect × constructs, F(6,134) = 6.75, P < 0.0001]. ***p < 0.001 (EVT901 versus untreated), ###p < 0.001 (untreated control versus untreated constructs). (G) Inhibition of specific p75NTR ligand-induced apoptosis. Subconfluent monolayers of SH-SYSY cells stimulated for 48 h with pro-NGF (10 ng/ml; solid blue line), or amyloid-b1-40 (10 μM; dashed black line), in addition to increasing concentrations of EVT901 (from 0.01 to 100 nM). (H) Induction of neuritogenesis through TrkA phosphorylation. SH-SYSY cells serum-deprived, and treated with rhNGF (10 ng/ml) or EVT901 (0.01 to 10 nM), and then maintained in the same media for 3 days. The neurite length was visualized after staining with May-Grünwald-Giemsa and digitally photographed from randomly selected image fields (magnification × 10). (I) Confluent SH-SYSY cells serum-deprived, and treated with NGF (10 ng/ml) or EVT901 (100 nM) for different times (1–3 days). Quantification of levels of total TrkA or phosphorylated TrkA (Tyr490) expressed as OD490 and representative of three independent experiments. Four-way ANOVA [time effect, F(2,18) = 21.0, P < 0.001; NGF effect, F(1,18) = 152.75, P < 0.0001; EVT901 effect, F(1,18) = 43.32, P = 0.052; pTrkA, not significant]. Note that there are significant interactions: time × NGF, F(2,18) = 33.81, P < 0.0001; time × EVT901, F(2,18) = 40.19, P < 0.0001; time × pTrkA, F(2,18) = 5.99, P = 0.01; NGF × pTrkA, F(1,18) = 167.68, P = 0.0001; EVT901 × pTrkA, F(1,18) = 43.79, P = 0.000010; time × NGF × pTrkA, F(2,18) = 50.54, P = 0.0001; time × EVT901 × pTrkA, F(2,18) = 25.23, P = 0.0001. ***p < 0.001 compared to untreated control. (J) Chemical structure of EVT901: 1-(phenyl-3, 6-dihydro-2H-pyridinyl)-2-(aryl-bridged piperazines)-ethanone.
Caspase activity assays

To detect apoptotic cell death, caspase activity was measured using a pan-caspase apoptotic detection kit (Carboxyfluorescein FLICA; Immunochemistry Technologies, LLC) according to the manufacturer’s protocol. Briefly, after treating cells with proNGF and EVT901 for 24 h, cells were washed with PBS twice and then the 30 × FLICA solution was added to the medium at a 1:30 ratio. Cells were incubated for 1 h at 37 °C in a CO2 incubator and protected from light. After washing cells twice with wash buffer, cells were fixed with 4% paraformaldehyde for 20 min. After washing with PBS, cells were mounted on slides containing a drop of mounting media (ProLong® Gold with DAPI, Invitrogen). The mounted cells were observed under a fluorescence microscope (Nikon) equipped with a digital camera (AxioCam, Zeiss) with 20 × objective and pictures taken in five different areas that contained ≥100 DAPI-positive cells. Double-positive cells and DAPI-positive cells were counted. Data were expressed as a percentage of double-positive cells against DAPI-positive cells: % positive cells = (number of double-positive cells/number of DAPI-positive cells × 100). Data were collected from three independent experiments.

Determination of p75NTR expression in oligodendrocyte precursor/oligodendrocyte cells

Cells were fixed with 4% paraformaldehyde for 20 min and then washed with PBS and treated with blocking buffer (10% goat serum/0.1% BSA/0.01% Triton® X-100) for 1 h at room temperature. Anti-rabbit p75NTR Ab (1:1000 dilution; COVANCE) was added and incubated overnight at 4 °C. For negative controls, no antibody was added. After washing cells with PBS three times, secondary antibody (goat anti-rabbit Alexa 488, 1:200, Molecular Probes) was added and incubated for 1 h at room temperature. Cells were washed with PBS three times and cover-slipped with mounting media (ProLong® Gold with DAPI, Invitrogen). The mounted cells were observed under a fluorescence microscope (Nikon) equipped with a digital camera (AxioCam, Zeiss) with a 20 × objective and pictures taken in five different areas containing >100 DAPI-positive cells. Double-positive cells and DAPI-positive cells were counted, and data were expressed as % positive cells versus DAPI-positive cells (number of double positive cells/number of DAPI-positive cells × 100). Data were collected from three independent experiments.

CCI-TBI and drug treatment

To generate the TBI, a controlled cortical impactor (Custom Design & Fabrication) was used as described previously (Inoue et al., 2013). Surgical procedures were carried out aseptically under anaesthesia induced and maintained by 2–3% of isoflurane anaesthesia. The toe pinch-reflex test was used to determine the effectiveness of the anaesthetic prior to surgery. Lacri-Lube® opthalmic ointment (Allergan Pharmaceuticals) was applied to the eyes prior to surgery. Body temperature was monitored using a rectal thermal probe and maintained at 37.5 ± 0.5 °C using a heating pad. Animals were administered 25 mg/kg of cefazolin (Ancef, Novation, LCC) prior to surgery and for 3 days postoperatively. Rats were mounted in a Kopf stereotaxic frame under isoflurane anaesthesia and maintained at 37.5 °C. A unilateral craniectomy was produced in the skull using a 6-mm diameter trephine positioned from 3 mm anterior to 3 mm posterior to bregma, and between 1.0 mm and 7.0 mm laterally from bregma. Moderate contusion brain injury was generated using the CCI device with a 5 mm diameter impactor tip positioned perpendicularly to the surface, of the left somato-motor cortex, using a 2.0 mm displacement at 4 m/s velocity, and a dwell time of 150 ms. The injury sites were closed and the animals were recovered in a Thermocare® Intensive Care Unit with Dome Cover (Thermocare, Inclined Village). Sham-injury controls had all procedures including the craniectomy but without cortical contusion.

To infuse EVT901, rats had a jugular vein catheter placed under anaesthesia. Animals were placed in a supine position, a longitudinal cut was made on the skin, and muscles were retracted to expose the left jugular vein. Polyethylene tubing (0.58 mm internal diameter × 0.96 mm outer diameter; BPE-T50 Solomon Scientific) cut to a length of 12.5 cm was used to introduce drugs (vehicle or EVT901) into the vascular system. A 1.5 cm portion of the tubing was inserted into the jugular vein, secured using a 4.0 silk suture and fed subcutaneously to the back of the animal, allowing easy access for repeated drug administration. EVT901 doses (0, 1, 3, and 10 mg/kg) were prepared and labelled to allow for blinding of the investigators administering the drugs. The code used for each group was revealed at the end of the study. The total volume of solution was determined by the weight of each rat. Five mg/kg (v/w) of prepared EVT901 (or vehicle) was infused over 2 min via an infusion pump (RS-300 Syringe Infusion Pump, Braintree Scientific). EVT901 was infused once per day for 7 days starting at 4 h post-injury. Blood was collected by tail vein within 15 min of the initial infusion on Day 1 and the final infusion on Day 7 to confirm infusion of EVT901. Approximately 60 μl of blood was blotted on 903 protein saver cards (Whatman) and dried at room temperature. Analysis of the coded blood spots showed that each drug treatment level resulted in the predicted blood levels (not shown). Sample size was determined by power calculations based on previous studies (Inoue et al., 2013) (n = 8–12 per group). Only data from animals surviving for the entire test period were included in the statistical analysis. Overall survival rate was 90%.

Western blot analysis of CCI-TBI tissue

Rats were perfused with PBS at 1, 2, 8, and 14 days post-injury. Brains were removed and the white matter region, cortex, and hippocampus were dissected for protein preparation. The tissue was homogenized in protein lysis buffer (1:5 ratio, Pierce IP Lysis buffer, Thermoscientific) including protease/phosphate inhibitor (Halt™ Protease and Phosphatase inhibitor cocktail, Thermoscientific), 5 mM EDTA and 1 mM PMSF and sonicated at 40 amplitude, 10 s pulse, two times. Protein lysate was obtained by centrifugation at 13 000 rcf for 10 min at 4 °C. Protein concentration was determined by the BCA protein assay kit (Pierce). Twenty micrograms of protein was added with Laemmli sample
buffer (Bio-Rad) including 20 mM DTT and β-mercaptoethanol and boiled for 5 min. Protein was loaded onto 4–20% tricine gel (Bio-Rad), electrophoresed, and transferred onto a PVDF membrane. After blocking the membrane with blocking buffer (Li-COR Bioscience), the membrane was incubated overnight at 4 °C with antibodies directed against p75NTR (1:1000, COVANCE, Cat # PRB-602C), proNGF (1:500, Millipore, Cat # AB9040), Cleaved caspase-3 (1:1000, Cell Signaling, Cat #. 9664), and β-actin (1:2500, Sigma). Membranes were washed three times for 5 min with PBS, secondary antibodies (anti-rabbit IR680 and/or anti-mouse IR800, 1:5000) were added and incubated for 1 h at room temperature. After washing membranes with PBS three times for 5 min, membranes were scanned with an Odyssey scanner (Li-COR Bioscience). Quantification was performed using the Odyssey scanner software (Li-COR Bioscience).

**Histology, immunocytochemistry and cell counts for CCI-TBI animals**

Rats were killed at 24 h or 8 days post-injury and transcardially perfused with PBS, followed by 4% paraformaldehyde. Brains were removed, post-fixed, and cryoprotected in 30% sucrose. Sections of 30 μm were cut on a cryostat (Microm). Sections were treated with blocking buffer (10% goat serum/0.1% BSA/0.01% TritonX-100) for 1 h at room temperature and stained overnight at 4°C with antibodies against p75NTR (1:200, COVANCE, Cat # PRB-602C), proNGF (1:100, Millipore, Cat # AB9040), Cleaved caspase-3 (1:100, Cell Signaling, Cat # 9664), APC (1:10, Millipore, Cat #Ab16794), GFAP (1:100, Millipore, Cat #345860), and CD11b (1:100, Serotec, Cat #MCA275R). After washing with PBS three times, secondary antibodies (1:200; anti-rabbit IR680 and/or anti-mouse IR800, 1:5000) were added and incubated for 1 h at room temperature. Slides were washed with PBS three times for 5 min, and were mounted with mounting media (ProLong Gold with DAPI, Invitrogen). Slides were analysed using a fluorescence microscope (Nikon) and images were captured with a digital camera (AxioCam, Zeiss).

**Volumetric analysis**

**The Cavalieri probe method**

To determine if EVT901 affects tissue damage after TBI, the estimated volume of the injured brain (including the 3 mm injured zone) was measured by systematic volumetric analysis. Briefly, at 8 days after TBI, the brains of paraformaldehyde perfused animals were collected and cut at 30 μm as described above. For each rat, 15 brain tissue sections (every 10 sections between +2.2 and −2.2 mm from Bregma) were chosen for stereological analysis and stained with Cresyl violet (Fig. 4D). The Cavalieri principle was used to generate unbiased estimates of volume using Stereo Investigator software (MBF Bioscience). As a Cavalieri probe, a 200-μm square grid was placed over the brain tissue section and all the grid points that overlay the areas of interest were marked. Areas included the hemisphere (Fig. 4B), cerebral cortex (Fig. 4C), and the white matter including the corpus callosum (Fig. 4C). All 15 brain tissue sections were evaluated by marking the grid points, which generate unbiased estimations of area. The volume was estimated by summing the areas and multiplying by the tissue thickness using Stereo Investigator software. Gunderson coefficient of error, m = 1, was evaluated to determine the accuracy of the stereological estimation and was <0.05 (not shown) in this study (n = 8–12 per group). Sample size was determined by power calculations based on previous studies (Inoue et al., 2013) (n = 8–12 per group).

**Stereological analysis**

**Counting APC-positive cells**

To determine if EVT901 protects oligodendrocytes from TBI, we quantify the number of oligodendrocytes in the white matter by unbiased stereological assessment. Briefly, a total of 10 brain sections were chosen for stereological analysis (every 330 μm interval between 1.5 mm anterior to 1.5 mm posterior to Bregma). Free-floating brain sections were stained with anti-CC1 antibody (APC clone) (1:100 dilution; Abcam, Cat #Ab16794) overnight at 4°C. After washing with PBS, tissues were incubated with biotinylated antibody (VECTASTAIN Elite ABC Kit, Vector Laboratories) for 30 min and visualized with 3,3′-diaminobenzidine (DAB) chromogen (ImmPACT™ DAB Peroxidase substrate, VECTOR Laboratories). To quantify the number of APC-positive cells for unbiased assessment, systematic random sampling using the optical fractionator method in the region of interest was performed with Stereo Investigator (Fig. 4C). The white matter was contoured with a 2× objective and cells counted with a 63× objective. A counting grid was set as 245 μm × 183 μm and placed randomly over the contoured white matter (Zhao et al., 2011). The counting frame was set as 30 μm × 30 μm with 3 μm guard zone (Lotocki et al., 2011). Section thickness was measured at each counting site and the average tissue thickness was computed for stereological calculation by Stereo Investigator software. Average of tissue thickness was 18.95 ± 0.45 μm (SEM). The total number of CC1-positive cells was automatically calculated by Stereo Investigator using the following equation: \( N = Q^-1 \times 1/ssf \times 1/asf \times 1/hsf \) (N is total neuron number, Q is the number of neurons counted, ssf is section sampling fraction, asf is the area sampling fraction, and hsf is the height sampling fraction). Coefficient of error, m = 1, was evaluated to determine the precision of the estimation of the stereological measurement. All Coefficients of error, m = 1, in each group was <0.05 (not shown; n = 5–7 per group).

**Counting NeuN-positive cells**

To determine if EVT901 preserves neuronal cells from TBI, we quantified the number of NeuN-positive cell in the cerebral cortex by unbiased stereological assessment. Briefly, seven brain sections were chosen for stereological analysis (every 330 μm interval from between bregma levels +1.2 and −1.2 mm). Free-floating brain sections were stained with anti-NeuN antibody (1:100 dilution; Millipore, Cat #ABN90) overnight at 4°C. After washing with PBS, tissues were incubated with biotinylated antibody (VECTASTAIN Elite ABC Kit, Vector Laboratories) for 30 min and visualized by DAB chromogen (ImmPACT™ DAB Peroxidase substrate, VECTOR Laboratories). To quantify the number of NeuN-positive cells, the optical fractionator method
was used by Stereo Investigator. The rhinal fissure was used as a landmark to identify the lateral aspect of the neocortex (Fig. 4C) (Weskamp and Reichardt, 1991). The cortical region was contoured to the border of rhinal fissure with a 2× objective and counting was performed with 63× objective. The counting grid was set as 350 μm × 265 μm and placed randomly over the contoured cortical region (Weskamp and Reichardt, 1991). The counting frame was set as 50 μm × 50 μm with a 3 μm guard zone. The section thickness was measured at each counting site and the average tissue thickness was computed for stereological estimate calculation by Stereo Investigator software. Average tissue thickness was 19.02 ± 0.2675 μm (SEM). The total number of NeuN positive cells was automatically calculated by Stereo Investigator using the following equation: \[ N = Q \times ssf \times 1/hsf \] (N is total neuron number, \( Q \) is the number of neurons counted, ssf is section sampling fraction, asf is the area sampling fraction, and hsf is the height sampling fraction). Coefficient of error, m, = 1, in this study was <0.05 (data not shown; n = 4 per group).

**Determination of myelin loss in white matter**

To determine the effect of TBI on myelin loss, eriochrome cyanine was used for staining. Briefly, brain tissue sections were chosen from bregma −900 μm, where the most damaged white matter area based on unbiased systematic volumetric analysis using Cavalieri probe (Supplementary Fig. 2). After defatting with acetone, tissues were stained with eriochrome cyanine solution (0.3% eriochrome cyanine, 0.5% H₂SO₄, and 10% iron alum) for 30 min at room temperature in 5% iron alum solution until white matter (blue) was clearly differentiated from grey matter. Then tissue sections were placed in borax-ferricyanide solution (1% borax and 1.5% potassium ferricyanide) for 10 min to complete differentiation. After rinsing with water, tissues were dehydrated and mounted with DPX mounting media (Sigma). Entire brain tissue images were captured with ×10 magnification and stitched by BZ-8100 (BIOREVO microscope, Keyence). To measure intensity of eriochrome cyanine staining, NIH ImageJ software was used. Briefly, the entire brain images were opened with ImageJ software, converted to 8 bit image, and contoured white matter areas in ipsilateral and contralateral hemisphere were indicated as the region of interest. To obtain only myelin-positive signal, the image was adjusted using bright/contrast by setting threshold to the grey scale range of 70–250 (Image J > Image > adjust images). Then the region of interest was selected and the integrated density measured (Image J > Integrated density > analyze > measurement). The integrated density value for contralateral was used for the internal control. Data are presented as a percentage (intensity of ipsilateral/intensity of contralateral) × 100 (n = 5 per group). The sample size was chosen based on preliminary data (n = 5 per group).

**Determination of microglia activation in white matter**

To estimate microglial activation, we used a proportional area measurement modified from previous reports (Popovich et al., 1999; Zhang et al., 2011). Five brain tissue sections at 600-μm intervals from Bregma +1.2 mm to −1.2 mm were measured from each rat. Briefly, brain tissue sections were treated with peroxidase block (Dako EnVision™ + System-HRP, DAKO) for 5 min, washed with PBS, and then incubated with CD11b Ab (1:100 dilution, AbD Serotec, Cat #MCA275R) for 1 h at room temperature. After washing with PBS, peroxidase-labelled polymer (Dako EnVision + System-HRP, DAKO) was applied for 30 min at room temperature. Tissues were washed with PBS and then visualized with DAB chromogen for 10 min. The reaction was stopped with distilled water. The stained sections were observed on a Zeiss microscope. For assessing CD11b-positive cells in the white matter, two different areas (157.5 × 101.6 mm) in the ipsilateral and contralateral side of brain from the corpus callosum were photographed under a 40× objective using a digital camera (Retiga EXi Fast1394, Qimaging). To measure the proportional area of reactive microglia, we used threshold measurement by MetaMorph® software (Molecular Devices). Briefly, images were opened with MetaMorph® software and the intensity of the background was measured using ‘Region Measurement’. Using ‘Set Color Threshold’, the threshold was set on the CD11b-positive signal, while the pre-measured background intensity was set as baseline (Metamorph > Set Color threshold). Once threshold was set, CD11b-positive signal was measured using Region Measurement. Data are presented as percentage (threshold area of CD11b-positive/total area) × 100 (n = 5 per group). The sample size was chosen based on preliminary data (n = 5 per group).

**Behavioural evaluation for motor recovery**

The paw placement test was performed as previously described (Inoue et al., 2013). Briefly, rats were placed in a clear plastic cylinder. The spontaneous behaviour of the rats was recorded with a digital camera for 3 min, and the number of times the rat placed its left, right, or both forepaws against the cylinder during weight supported movements was determined. Individual placements were scored as ‘left’, ‘right’, or ‘both’. Scoring was performed using video playback by two trained raters independently in a blinded manner. Rats were tested before surgery and on Days 2 and 7 after TBI. Sample size was determined by power calculations based on previous studies (Inoue et al., 2013) (n = 8–12 per group).

**Fluid percussion traumatic brain injury and outcome measures**

Male Sprague Dawley rats (strain RJHan; Janvier) (170–230 g) were anaesthetized with sodium pentobarbital for trauma, placed in a stereotaxic frame, and a hole (4 mm in diameter) was made at the level of the right parietal cortex (the centre being located 3.5 mm posterior to bregma, 7 mm lateral to the midline and 3.5 mm below the upper surface of the skull). A 1.6 mm internal diameter Teflon tube was placed in contact with the dura and fixed into the craniotomy with dental acrylic cement. The tube was connected to a Beckman HPLC pump and was filled with sterile injectable water. An FPI of moderate intensity (5 bar) was induced by a brief opening of the electronically controlled solenoid valve (100 ms). Thereafter, the tubing was removed, the scalp sutured and animals placed...
under a heating lamp for recovery from anaesthesia. The mortality rate was ~5%. The severity of injury was confirmed by assessing cognitive deficits. Sham rats were surgically prepared in the same manner but did not undergo craniotomy. EVT901 or its vehicle was administered orally by intragastric gavage (5 ml/kg in a solution of 0.6% methylcellulose/0.5% Tween 80), once a day, 24 h after the surgery, and for 23 days.

**Behavioural evaluation of memory deficits**

**Object recognition test**
Memory assessment was performed 5 days after the end of treatment on Day 28 post-injury. The test consisted of three sessions. The first session was for habituation (exploration for 3 min, record of the time spent in active movements). The second at 24 h later, was the acquisition session; the rat was placed in the box with two identical objects located in opposite corners, and the time to achieve 20 s exploring those two objects was recorded (limit of 6 min). Rats were replaced in the box 1 h later, for the third recall session of 5 min, with a previously presented familiar object and a novel object. Time spent exploring the familiar (F) and the novel (N) objects was recorded. Others parameters calculated from the recall session: total exploratory time (N + F) and the novelty index (N − F/N + F).

**Conditioned freezing response test**
Memory deficits were evaluated using the conditioned freezing response test. Rats were conditioned to associate the context with a foot shock, and then tested for fear-associated freezing to the context. Briefly, two sessions, 24 h apart were used. First, rats were introduced to the experimental box where they received a scrambled electric foot-shock (0.6 mA, 1.5 s). In the second session, the rats were replaced in the same box for 3 min, and the duration of freezing (complete lack of movement except for breathing) was recorded.

**Behavioural evaluation of seizure susceptibility**

**Epileptogenesis**
To detect any enhanced seizure susceptibility in post-TBI rats, a kainate sensitivity test was performed 42 days after the traumatic injury and 5 days after the last administration of the compound EVT901 (1 mg/kg/day, oral administration for 42 days). Evaluation of the increased susceptibility of rats to seizure induction by kainate was determined after a single injection of sub-convulsant dose of kainate (8 mg/kg, intraperitoneally). Movement was evaluated from 45 min to 3 h 45 min post-kainate injection: each rat was observed and convulsions were scored into five classes by a standard method (Racine’s score) (from stage 1: immobility, to stage 5: forelimb clonus, rearing and loss of postural tone). For each group, a status epilepticus was defined, corresponding to the per cent of rats that reached continuous seizure activity in the different groups.

**Immunohistochemistry**

**p75NTR and Fluoro-Jade® staining**
Free-floating tissue sections were incubated overnight at 4 °C with anti-p75NTR antibody (1:1000, Millipore) in PBS-T/sodium azide (0.02%), then with secondary antibody (Vector Vectastain ABC kit) and avidin-biotin-peroxidase complex (Vector Laboratories). Sections were visualized using a DAB substrate kit for peroxidase (DAB kit, DAKO), mounted on glass slides, air dried, alcohol dehydrated and cover-slipped with Eukitt® mounting medium (Eukitt EMS). For Fluoro-Jade® staining, tissue sections were directly mounted onto DAKO-Flex slides, hydrated and incubated in a solution of potassium permanganate. After incubation in a solution of Fluoro-Jade® B (Chemicon), sections were air-dried, immersed in xylene, cover-slipped as previously, and visualized using FITC fluorescence microscopy. Digital images were collected and Fluoro-Jade B-positive cells were subsequently counted using Explora Nova software; averages were used for statistical analysis.

**Randomization and blinding**
All animal studies were performed with randomized treatment allocation and outcomes assessed by experimenters blind to condition.

**Statistical analysis**
Analysis of all biochemical, histological and behavioural data was performed in SPSS v.19 (IBM) by an independent statistician. One-way, two-way (or higher order) balanced, factorial analysis of variance (ANOVA; SPSS General Linear Model command) was used to explicitly test each factor in the balanced factorial experimental designs. The statistical approach ensured two-tailed, balanced testing of main effects and interactions across all factorial combinations of treatments. Technical replicates and independent experiments were statistically treated as random effects, thereby correcting for technical variance to directly test treatment effects conserved across replicates. Comparison of two groups was performed by an unpaired, two-tailed Student’s t-test. For behavioural analysis of cognitive/motor function, mixed factorial repeated measures ANOVA was used. Sample sizes (n) were justified by power calculations and all analytics were applied after checking for statistical assumptions (normality, homogeneity of variance, sphericity). Statistical significance was defined at P < 0.05. Data are expressed as means ± SEM. F-values and degrees of freedom are reported in figure legends.

**Results**

**EVT901 inhibits p75NTR signalling, blocks apoptosis, and activates TrkA**
To determine whether a small molecule could bind to p75NTR and disrupt the preassembly step (Chan, 2007), we set up a screen to detect protein/protein interaction with reliable quantification. The soluble truncated form of p75NTR, containing only the four CRDs fused to alkaline
phosphatase (AP-p75NTR), was used as ligand and probe to detect p75NTR oligomerization on SK-N-Be human neuroblastoma cells stably transfected with full-length p75NTR (SK-N-Be-p75NTR). More than 400 molecules, selected from a library of compounds active on a phenotypic model of neurogenesis, were screened for their ability to inhibit the pre-oligomerization of p75NTR (ligand-independent). Thus, a dedicated chemical program allowed us to select new leads characterized by aryl substituted piperazine and showing nanomolar activity. From the structure/activity relationship analysis, an oriented second back-screening campaign, in particular with introduction of bridged piperazines replacing the piperazine moiety, led us to select a new chemical series [1-(phenyl-3, 6-dihydro-2H-pyridinyl)-2-(aryl-bridged piperazines)-ethanone] with high potency, specificity and selectivity; those compounds were also screened in vitro to inhibit apoptosis in neuroblastoma cells. Through the optimization process, we identified EVT901 (Fig. 1J) as a highly active compound with sub-nanomolar potency; and a full characterization of its selectivity and ADME (absorption, distribution, metabolism and excretion) in vitro and in vivo properties was carried out. EVT901 showed a high ability to inhibit the binding of AP-p75NTR to p75NTR in a dose-dependent manner, with sub-nanomolar potency (IC50 of 0.21 ± 0.04 nM) (Fig. 1A). EVT901 also alters NGF binding to p75NTR (Fig. 1B).

To determine whether a specific self-association domain (PLAD) is present on the p75NTR and if EVT901 can interfere with its oligomerization (Chan et al., 2000), we co-expressed full-length HA-p75NTR and Flag-p75NTR tagged receptors in HEK293T cells. High levels of Flag-p75NTR association with the HA-p75NTR were observed when both receptors were co-expressed, demonstrating that p75NTR is able to self-oligomerize independently of ligand binding (Fig. 1C). Interestingly, EVT901 dose-dependently reduced this association, suggesting that EVT901 can interfere with p75NTR pre-oligomerization. To confirm that EVT901 interferes directly at the level of a PLAD (Gentry et al., 2004), we designed different mutated and chimeric receptors (Fig. 1E). Transfection efficiency of these chimeric receptors was confirmed using an anti-HA antibody to detect surface expression using flow cytometry. Expression of the various constructs was between 85% and 95% of cells (data not shown). Consistent with a previous study (Ye et al., 1999), overexpression of full-length p75NTR induced spontaneous apoptosis, which was significantly abrogated by EVT901 at 100 nM (Fig. 1D). Overexpression of a deleted form of p75NTR (CRD1-p75NTR) also induced high levels of apoptosis, which was strongly reduced in the presence of EVT901. Moreover, EVT901 was not able to abrogate CD40-induced apoptosis, clearly suggesting its specificity for p75NTR. Although specific deletions may disrupt receptor structure, we generated a chimeric receptor by exchanging the first CRD of CD40 receptor with the CRD1 of p75NTR and confirmed that expression of this chimeric receptor on HEK cells induced strong spontaneous apoptosis, similar to wild-type cells (Fig. 1D and E). In this model, EVT901 showed anti-apoptotic activity confirming that the site of interaction of EVT901 is located on the CRD1 of p75NTR (Fig. 1D). The specificity of EVT901 to p75NTR versus other members of the TNFR superfAMILY (TNFR1, TNFR2, HVEM, 4-1BB, LTβR, DR5, BCMA, FAS) was further confirmed by demonstrating that EVT901 does not inhibit apoptosis of HEK293T cells induced by overexpression of these receptors (Fig. 1F). As a follow-up to the p75NTR-overexpression models, it was essential that EVT901 was also able to abrogate p75NTR signalling in a cell type expressing endogenous p75NTR. Therefore, we confirmed the neuroprotective effects of EVT901 on SH-SY5Y cells, where apoptosis is induced by pro-NGF (IC50 of 0.51 ± 0.16 nM) (Fig. 1G).

Well known to exhibit prevalent β-sheet structures and to form fibrillar aggregates, the prion protein (PrPT106–126) and amyloid (amyloid-β1–40) peptides induce pro-apoptotic signalling via p75NTR. We hypothesized that the interaction site(s) of these peptides on p75NTR are different from that of the neurotrophins, and could be located in the CRD1 domain of p75NTR. We first evaluated the effect of these two aggregated peptides on apoptosis in SH-SY5Y cells. Incubation with PrPT106–126, or amyloid-β1–40, increased cell death (not shown). Interestingly, EVT901 was able to strongly reverse apoptosis induced by these two aggregated peptides with IC50s of 0.69 ± 0.30 nM for PrPT106–126 and 0.42 ± 0.11 nM for amyloid-β1–40 (Fig. 1G). Moreover, the potency of EVT901 against apoptosis induced by these peptides suggests that the functional epitope on p75NTR is able to self-oligomerize independently of ligand binding. EVT901 acting on the domain of p75NTR interacts with PrPT106–126 and amyloid-β1–40, is located on the CRD1 domain. This hypothesis was further supported by the pro-apoptotic efficacy of these peptides on the short form of p75NTR containing only CRD1 in the extracellular part.

Previous findings suggest p75NTR mediates NGF-induced neuronal cell survival and neurite outgrowth by regulating the TrkA-mediated signalling pathway. We tested whether EVT901 interferes with TrkA-dependent neurite outgrowth on SH-SY5Y cells expressing both TrkA and p75NTR. Increasing concentrations of EVT901 induced extensive neuritogenesis in a dose-dependent manner, as compared to untreated controls (Fig. 1H), suggesting that EVT901 can modulate TrkA activity by facilitating the interaction of p75NTR monomers with TrkA. To further validate this hypothesis, we showed that the level of TrkA phosphorylation is strongly increased by stimulation with rhNGF (Fig. 1I), and EVT901 dramatically increased TrkA phosphorylation after 3 days of treatment, correlating with the induction of neurite outgrowth (Fig. 1J).

ProNGF has been shown to induce caspase activation and apoptosis in cultured oligodendrocytes via p75NTR (Beattie et al., 2002). Here we tested if EVT901 would reduce this pro-NGF-induced apoptosis in mature oligodendrocytes and OPCs in culture, and show that adding
proNGF for 24 h increased p75NTR expression and caspase activation, and a wide dosing range of EVT901 inhibited both (Fig. 2). Thus, EVT901 may provide protection from proNGF toxicity by both reducing expression of p75NTR and by blocking proNGF-induced p75NTR oligomerization and apoptotic signalling.

**EVT901 is protective in a unilateral CCI-TBI model and improves outcomes**

CCI-TBI transiently increased p75NTR protein level at 1 and 2 days post-injury in the ipsilateral white matter (Fig. 3A and B). Immunostaining revealed that p75NTR was co-localized in CC1 positive cells at 24 h following CCI-TBI, suggesting that injury induces p75NTR-expression in oligodendrocytes, as reported after spinal cord injury (Beattie et al., 2002) (Fig. 3B). p75NTR was not co-localized in GFAP+ astrocytes (not shown). Western blot analysis showed a rapid (and longer) transient increase in proNGF after TBI, returning to normal at 14 days (Fig. 3C) and this could induce apoptosis in oligodendrocytes in the subcortical white matter. Indeed, western blots using an antibody to cleaved caspase-3 revealed a significant increase in expression by 8 days after TBI (Fig. 3E), similar to that seen in the dorsal columns after spinal cord injury (Beattie et al., 2002; Sun et al., 2010). Evidence for co-localization of CC1 and cleaved caspase-3 in immunostained sections was seen as early as 1 day post-TBI (Fig. 3F). In addition, p75NTR protein levels were significantly increased in both cortex after TBI (Supplementary Fig. 1), suggesting that p75NTR is also involved in neuronal cell death in vivo.

Cerebral, cortical, and subcortical white matter volumes, measured using unbiased stereological methods at 8 days post-TBI (Fig. 4), were significantly reduced by TBI, and EVT901 dose-dependently mitigated the loss (Fig. 4F, G and Supplementary Fig. 2A and B). Using stereological estimates of oligodendrocytes in the subcortical white matter.
Figure 3  Induction of p75NTR and proNGF in the white matter (corpus callosum) after CCI-TBI. (A–D) Immunoblot analysis showed that both p75NTR and proNGF protein levels are increased after TBI in the ipsilateral white matter as compared to uninjured (UN) and sham injured tissue. Two-way ANOVA, (A) for p75NTR: side, \( F(1,12) = 92.42, P < 0.0001 \); time, \( F(5,12) = 32.32, P < 0.0001 \); (C) for proNGF: side, \( F(1,12) = 126.54, P < 0.0001 \); time, \( F(5,12) = 18.18, P < 0.001 \). In ipsilateral white matter, p75NTR and proNGF are significantly increased \( [F(5,12) = 32.55, P < 0.0001 \) and \( F(5,12) = 11.72, P < 0.0001 \), respectively]. (B) P75NTR immunoreactivity is co-localized with CC1 expression in cells with oligodendrocyte morphologies (arrowheads). Scale bar = 20 μm. (D) ProNGF immunoreactivity is co-localized in CD11b-positive and GFAP-positive cells (arrowheads), suggesting that microglia and astrocytes are responsible for proNGF expression in the corpus callosum at 1 day after TBI. Scale bars = 50 μm. (E) Immunoblot analysis showed that TBI increased the cleaved caspase-3 expression on the ipsilateral side compared to the contralateral side at 8 days after injury [side, \( F(1,12) = 6.78, P < 0.05 \); time, \( F(5,12) = 6.02, P < 0.01 \)]. In the ipsilateral white matter, cleaved caspase-3 protein level is significantly increased \( [F(5,12) = 6.02, P < 0.01 \). *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.00005, ####P < 0.01 compared to sham; n = 3/group; Error bars indicate ± SEM. (F) Cleaved caspase-3 immunoreactivity is co-localized in CC1 positive oligodendrocytes (arrowheads). Scale bar = 50 μm. *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.00005, ####P < 0.01 compared to sham.
Figure 4  EVT901 treatment reduced atrophy in grey and white matter at 8 days post injury. (A) The region of interest (ROI) included tissue from 3 mm anterior to 3 mm posterior to bregma. (B and C) Illustration of representative brain figures of the hemisphere (B) and cerebral cortex and white matter (C), where stereological methods were used to estimate tissue volume by counting Cavalieri markers using Stereo Investigator. (C) The region of interest included the cerebral cortex from the midline to the rhinal fissure (small arrowhead); the ipsilateral cerebral cortex is indicated in red versus the contralateral cerebral cortex in blue, and ipsilateral white matter is indicated in pink whereas light blue indicates contralateral white matter. (D) Representative brain tissues stained with Cresyl Violet. Scale bar = 1 mm. (E) Total estimated volume was measured in each hemisphere. Total volume did not change between the ipsilateral and contralateral hemispheres at 8 days post-injury. (F) Total cortical volume estimates revealed significant atrophy of cortex on the ipsilateral but not contralateral side after TBI [two-way ANOVA, side, \( F(1,45) = 101.09, P < 0.001 \); \(^*P < 0.05\) compared to sham. However, EVT901 treatment was protective on the ipsilateral side [dose \( \times \) side, \( F(4,45) = 2.69, P < 0.05 \); \( n = 8–12\) per group. (G) Total white matter volume was also significantly reduced ipsilateral to the injury [side effect, \( F(1,45) = 17.51, P < 0.001 \); dose effect, \( F(4,45) = 2.22, P > 0.05 \)]. EVT901 treatment preserved white matter volume on the ipsilateral side [side \( \times \) dose, \( F(4,45) = 2.98, P < 0.05 \). \(^*P < 0.05\) compared to sham, \(^{#P < 0.05}\) compared to 0 mg/kg. Error bar indicates \( \pm \) SEM.
TBI significantly reduced CC1-positive oligodendrocytes and EVT901 treatments partially prevented this loss. Stereological counts of spared NeuN-positive cells in the cortical lesion area showed significant loss after TBI, and a protection after EVT901 treatment (Fig. 5C and D). Further, EVT901 treatment preserved myelin when compared to vehicle controls (Fig. 6A and B).

Using OX-42 staining density as a measure of microglial activation in tissue sections from vehicle and EVT901-treated (1 mg/kg) animals (Fig. 6C and D), EVT901 reduced microglial activation. Microglial activation has been shown previously to be associated with the loss of CC1 positive oligodendrocytes by apoptosis (Shuman et al., 1997; Sun et al., 2010).
Paw use for exploration in a cylinder is significantly reduced on the side contralateral to a cortical injury (Inoue et al., 2013). This was also partially preserved by EVT901 treatment (Supplementary Fig. 2E).

Oral EVT901 improves long-term outcomes in another TBI model

The results of our CCI-TBI studies provide evidence for a neuroprotective effect of EVT901 when the drug is given intravenously over 7 days; there is a clear positive effect on oligodendrocytes and white matter integrity, neuronal protection, and at least one sensorimotor function test. To examine the generality and persistence of these results, EVT901 was administered over a longer time course in another TBI model where trauma is induced by a focal lateral fluid percussion injury of the parietal cortex (FPI-TBI).

Similar to the effects of CCI-TBI, FPI-TBI produced an early expression of p75NTR at 1–2 days post-injury in the dentate gyrus, a structure where damaged neurons were also observed (Fig. 7A and B). Particularly vulnerable to FPI-TBI, the thalamus manifested marked positive Fluoro-Jade® staining at 14 days post-TBI (Fig. 7C). EVT901 significantly decreased Fluoro-Jade®-positive cells...
(324.3 ± 54.1 cells) in the dorsal thalamus on the injured side as compared to the vehicle (741.8 ± 138.4 cells) (Fig. 7D).

Furthermore, EVT901 administered orally beginning at 24 h and then daily for 23 days, dose-dependently restored object recognition performance and significantly improved the ability of rats to discriminate between objects compared to sham-treated animals (Fig. 8A–C). Time spent by treated rats on novel versus the familiar objects was significantly and dose-dependently increased at 1 and 3 mg/kg/day, and full recovery was observed after 23 days exposure (Fig. 8A and B). There was a significant increase in the novelty index, as reflected by total exploration time (Fig. 8C).

FPI-TBI induced a 75% reduction in the freezing response compared to sham; EVT901 significantly reinstated freezing durations at 0.3 and 1 mg/kg/day (84% and 88% recovery, respectively) (Fig. 8D). These studies suggest that EVT901 abrogates memory deficit induced by FPI-TBI.

TBI has been associated with increased seizure activity, so the effect of EVT901 treatment on hypersensitivity to a pro-convulsive agent was evaluated. Six weeks after injury, a subconvulsive dose of kainate elicits full-blown generalized tonic-clonic seizures (status epilepticus) in 90% of the rats with TBI (Fig. 8F). EVT901 treatment significantly decreased the intensity of post-TBI seizures (Fig. 8E), as well as the susceptibility to post-TBI seizures (Fig. 8F), further reinforcing EVT901’s pharmacological potential for treating CNS trauma.
The present results provide evidence that interfering with the oligomerization of p75NTR using the novel compound, EVT901 that interacts with the CRD of the extracellular domain of the molecule, is neuroprotective. P75NTR is structurally and functionally related to the TNFR superfamily. Although oligomerization is considered as the first signalling event induced by TNFRs, several studies indicate the presence of a pre-ligand binding assembly domain (PLAD) within the first cysteine-rich domain (CRD1) of the TNFR extracellular domain that mediates the pre-assembled oligomerization of the receptors prior to ligand stimulation (Chan, 2007). Such a PLAD domain has not been identified in p75NTR. Further, part of the pre-ligand binding oligomerization also has been attributed to cysteine bond formation in the transmembrane domain of p75NTR (Vilar et al., 2009, 2014). However, reports show that mutations in CRD1 abrogate neurotrophin binding to the receptor, consistent with the possibility of an assembly event mediated by CRD1 as prerequisite for ligand binding (Baldwin and Shooter, 1995). In addition, a PLAD peptide from TNFR1 blocks TNF or collagen-induced arthritis in vivo, highlighting the PLAD region as an interesting pharmacological target for TNFRs (Deng et al., 2005).

In this context, we developed a novel screening assay based on specific receptor binding that focused on the ligand-independent oligomerization of the p75NTR. Our

Discussion

The present results provide evidence that interfering with the oligomerization of p75NTR using the novel compound, EVT901 that interacts with the CRD of the extracellular domain of the molecule, is neuroprotective. P75NTR is structurally and functionally related to the TNFR superfamily. Although oligomerization is considered as the first signalling event induced by TNFRs, several studies indicate the presence of a pre-ligand binding assembly domain (PLAD) within the first cysteine-rich domain (CRD1) of the TNFR extracellular domain that mediates the pre-assembled oligomerization of the receptors prior to ligand stimulation (Chan, 2007). Such a PLAD domain has not been identified in p75NTR. Further, part of the pre-ligand binding oligomerization also has been attributed to cysteine bond formation in the transmembrane domain of p75NTR (Vilar et al., 2009, 2014). However, reports show that mutations in CRD1 abrogate neurotrophin binding to the receptor, consistent with the possibility of an assembly event mediated by CRD1 as prerequisite for ligand binding (Baldwin and Shooter, 1995). In addition, a PLAD peptide from TNFR1 blocks TNF or collagen-induced arthritis in vivo, highlighting the PLAD region as an interesting pharmacological target for TNFRs (Deng et al., 2005).

In this context, we developed a novel screening assay based on specific receptor binding that focused on the ligand-independent oligomerization of the p75NTR. Our
unpublished data indicated that consistent with previous findings (Vilar et al., 2009), the CRD1 domain is important for oligomerization for inducing apoptosis with a mutant lacking CRD1 domain (data not shown). Therefore, our study first identified a potent small molecule, EVT901, which directly inhibits the pre-oligomerization of the p75NTR through its extracellular domain (CRD1 domain) at sub-nanomolar concentration.

Interestingly, a very recent study suggests that p75NTR coexists as a trimer along with a monomeric form at the cell surface (Anastasia et al., 2015). However, trimerization was found not to be required for signalling (Anastasia et al., 2015). The authors suggest that monomers of p75NTR are sufficient to induce apoptotic cell death and that oligomerization of p75NTR prevents cell death (Wang et al., 2000; Anastasia et al., 2015). Although we have not tested whether EVT901 affects trimerization of p75NTR, the inhibition of p75NTR oligomerization by EVT901 was supported by additional studies showing an inhibition of what we interpreted as oligomerization in a ligand-independent manner, after overexpression of tagged-p75NTR. This result suggests, for the first time, the presence of a specific self-association domain in the extracellular region of p75NTR, but does not rule out the possibility of trimerization. EVT901 also alters the ability of NGF to bind p75NTR (Fig. 1). Moreover, EVT901 is unable to bind to other TNFRs, confirming its specificity for p75NTR (Fig. 1). Interestingly, CRD1-p75NTR, the shorter form of p75NTR induced strong apoptosis and this is totally abrogated by EVT901 (Fig. 1).

The short p75NTR variant (s-p75NTR) has also been described and the complete absence of both p75NTR isoforms displays more severe phenotypes, but also leads to a persistent increase in the number of cholinergic neurons in the medial septum (von Schack et al., 2001; Naumann et al., 2002; Roux and Barker, 2002). Given the significance of cholinergic forebrain neurons in learning and memory processes and their degeneration in Alzheimer’s disease, targeting p75NTR seems to be essential with regard to the modulation of the neuronal survival. S-p75NTR has been also reported to bind to Rabies virus glycoprotein through CRD1, and failed to bind neurotrophins (Langevin et al., 2002).

Although p75NTR binds all neurotrophins with similar nanomolar affinities, this receptor also interacts with pro-neurotrophins (pro-NGF) and non-neurotrophin ligands including the neurotoxic aggregated prion protein fragment PrP<sub>106–126</sub> and amyloid-β peptide. Increased expression of these ligands promotes apoptosis in cultured neuronal cells and animal models of neurodegenerative diseases through activation of a p75NTR-dependent mechanism (Hempstead, 2002). Our studies show that pro-NGF, PrP<sub>106–126</sub> or amyloid-β ligands trigger cell death in neuroblastoma cells and these pro-apoptotic effects are strongly reduced by EVT901. Moreover, PrP<sub>106–126</sub> and amyloid-β<sub>1–40</sub> induce strong apoptosis in HEK cells transfected with full-length p75NTR or CRD1-p75NTR and are ineffective on the CRD1-deleted form of the receptor. While the precise binding site of both neurotoxic peptides on p75NTR has not been determined, our results suggest that their functional epitopes may be different from that of these neurotrophins and are probably located at the level of CRD1. Moreover, EVT901 could represent an innovative therapeutic approach for the treatment of many neurodegenerative diseases where neurotoxic p75NTR ligands are involved.

Many neuronal cells co-express Trk receptors and p75NTR that could form a high affinity binding complex with specificity in neurotrophin binding, and thus enhance Trk signalling and subsequent neurotrophic effects (Roux and Barker, 2002; Gentry et al., 2004; Underwood and Coulson, 2008). EVT901 prevents ligand-independent apoptosis on cells overexpressing p75NTR, but also ligand-induced apoptosis in neuroblastoma cells expressing both p75NTR and Trk receptors, mainly by interfering directly with p75NTR oligomerization. Moreover, EVT901 stimulates neurite outgrowth, perhaps by enhancing the interaction between p75NTR and TrkA receptors, as supported by enhanced TrkA phosphorylation. Therefore, shifting the balance between p75NTR homo- to hetero-oligomerization can positively modulate the TrkA signalling pathway. Such modulation might be observed for other Trk receptor signalling pathways, such as TrkB, thereby increasing BDNF response, which could be beneficial in a wide range of contexts, particularly Huntington’s disease. The ability of EVT901 to inhibit p75NTR death signalling and to enhance Trk, leading to both neuroprotective and neurotrophic signalling in vitro, suggests that this compound may be a disease-modifying drug candidate for the treatment of neurodegenerative disorders and/or CNS injury. Indeed, the beneficial effects of long-term treatment after TBI shown in our FPI-TBI study could reflect enhanced neural plasticity related to these neurotrophic effects. In addition, a recent study showed that proBDNF, which interacts with p75NTR, suppresses neuronal remodelling and synaptic plasticity in cleavage-resistant proBDNF knock-in mice (Yang et al., 2014). Although we have not examined the potential involvement of proBDNF in our TBI studies, we can speculate that EVT901, through blocking p75NTR oligomerization, reduces proBDNF-induced p75NTR signalling in pathology after TBI. P75NTR has been shown to be upregulated in spinal cord injury, and to mediate apoptosis of oligodendrocytes via proNGF (Beattie et al., 2002). Injury-induced apoptosis of oligodendrocytes appears to be related to cellular stress and inflammation (Sun et al., 2010). Oligodendrocytes are also vulnerable to cell death in TBI and exhibit caspase-3 activation (Lotocki et al., 2011). Here, we expanded that recent finding by showing that a CCI-TBI-induced rapid and transient expression of p75NTR, proNGF, and caspase-3, and that p75NTR was expressed in CCI-positive oligodendrocytes in the subcortical white matter. Thus, EVT901 given during the week after CCI-TBI preserved tissue integrity in the cortex and
corpus callosum, spared CC1-positive oligodendrocytes in the white matter and NeuN-positive cells in the cerebral cortex, and positively impacted neurological function.

Using a different TBI model, we gave tests of memory function to rats with FPI-TBI at 1 week following cessation of a 23-day EVT901 or vehicle oral delivery regimen. FPI-TBI produced severe memory deficits, indicated by the inability to recognize novel objects and by a severe reduction in freezing responses in the conditioned freezing paradigm. Daily oral administration of EVT901, beginning 24 h post-injury, significantly prevented the TBI-induced memory deficit with full recovery at 1 mg/kg/day. Interestingly, a 1-week treatment with EVT901 is sufficient to induce significant memory recovery (data not shown).

Moreover, significant cell death was observed in the hippocampus from 1–4 weeks after TBI and preceded emergence of kainite-induced hypersensitivity (Routbort et al., 1999; Covolan and Mello, 2000; Dechant and Barde, 2002). In addition to its effects on cell death, and neurological and cognitive outcomes, EVT901 also significantly reduced TBI-induced hypersensitivity to pro-convulsive agents (Fig. 8E). EVT901 treatment also considerably reduced the percent of rats exhibiting status epilepticus (prolonged seizures induced by pro-convulsive agents), a condition that induces marked alterations in neurotrophin expression and persistent apoptosis in hippocampal, piriform, and entorhinal cortical neurons, mediated to a large extent by activation of p75NTR signalling. Regarding the effect of EVT901, we hypothesize that blocking oligomerization of the p75NTR could prevent activation of the receptor alone or through its interaction with pro-neurotoxphins, and might be related to the neuroprotective effects observed with EVT901 during the first week following trauma. Such effects may also prevent the decrease of mossy fibres and thus the abnormal sprouting process responsible for epileptogenesis.

The results of these two in vivo experiments suggest that proNGF-induced cell death, mediated by p75NTR, occurs in both neurons and oligodendrocytes after injury, and may contribute to both sensorimotor and cognitive dysfunctions after TBI. Post-injury microglial activation may lead to astrogliosis, and both activated microglia and astrocytes could be sources of proNGF leading to neuronal death through p75NTR signalling (Domeniconi et al., 2007). P75NTR could also mediate apoptotic neuronal cell death during axonal degeneration (Harrington et al., 2004). White matter injury, which leads to myelin debris fragments binding to Nogo receptor, may involve P75NTR signalling that contributes to axonal retraction and inhibition of endogenous repair mechanisms (Hempstead, 2006; Deinhardt et al., 2011). Indeed, recent reports have shown that a different small molecule (LMA11-31A) that reportedly affects P75NTR signalling by different mechanisms can reduce cell death and enhance neurological function following spinal cord injury (Tep et al., 2013), and can reduce the deleterious effects of TBI on adult neurogenesis (Shi et al., 2013). Unlike LMA11-31A, which inhibits the binding of proNGF to p75NTR (Shi et al., 2013; Tep et al., 2013), EVT901 blocks the interaction of p75NTR through the CRD1 domain, resulting in prevention not only proNGF, but also proNTs and oligomers (such as amyloid peptide and prion peptide), that directly interact with p75NTR. Due to these specific mechanisms of EVT901, p75NTR could still interact with other co-receptor (such as Trks) to promote neuroregenerative effects including neurite outgrowth and neurogenesis.

Thus, EVT901, through direct interaction with p75NTR, could modulate multiple intracellular signalling mechanisms, including reducing the initial neuronal damage and subsequent axonal degeneration, and increase memory recovery. By activating neuronal repair, EVT901 may limit the secondary injury due to progression of the lesion, enhancing cognition and reducing the risk of hypersensitivity to pro-convulsive agents. Future studies are needed to further elucidate whether inhibitors of p75NTR oligomerization can promote neurogenesis and restore brain function after TBI. Recent reports from other laboratories certainly seem to support this approach (Shi et al., 2013; Sebastiani et al., 2015).

In summary, this study is the first report of a small molecule inhibitor of p75NTR pre-oligomerization, which directly interacts with the CRD1 domain of this receptor, strongly suggesting the presence of a PLAD domain. In addition, these results highlight the potential benefit of targeting the PLAD as a novel therapeutic approach to prevent activation of TNF receptor superfamily members. The novel mechanism of action of EVT901, its potency and selectivity, its ability to simultaneously block p75NTR death signalling and promote neuroprotective and neurotrophic effects make this a potentially useful compound for the treatment of TBI and other neurodegenerative diseases.

Acknowledgement
We would like to thank Xiaokui Ma for technical support in tissue sectioning.

Funding
This work was supported by NIH NS038079, with statistical support from NIH NS067092, UCSF/BASIC pilot funds, and a sponsored research agreement (SRA) between Sanofi R and D and UCSF.

Conflict of interest
EVT901 (formerly SAR127963) was developed by authors affiliated with Sanofi R and D. The license has now been transferred to Evotec, Inc, of which S.D-G. and F.B. are now employees. M.S.B. and S.L. received partial salary
p75NTR mediates pathology after TBI

References


von Schack D, Casademunt E, Schweigerger R, Meyer M, Bibeil M, Dechant G. Complete ablation of the neurotrophin receptor...